Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Q BioMed says all convertible notes and loans now settled

Last month, hares rose as it welcomed an autism language expert to its advisory committee
Q BioMed says all convertible notes and loans now settled
The company is interested in various biotech assets

Q BioMed Inc (OTCQB: QBIO), a biotechnology acceleration company, said all its convertible notes and loans have been settled in full.

The company ended its 2017 financial year with no outstanding loans or convertible debt, it added.

"We are very pleased to end the fiscal year with a strong balance sheet and with a solid capital and financial structure from which to continue to build our business," said Denis Corin, chief executive.

Last month,  the company's shares rose as it welcomed an autism language expert to its  advisory committee for its candidate for non-verbal disorder in toddlers.

Dr Helen Tager-Flusberg has provided the protocol for capturing the primary endpoint of the planned trial for QBM-001.

Around 20,000 new cases of the disorder  are diagnosed in the USA each year and a similar amount in Europe.

The condition is one that affects very young (1 to 2yrs of age) children who are on the autistic spectrum.

The result is known as a ‘non-verbal disorder’ and is accompanied with developmental delay, where the toddlers either never learn to speak or lose the ability to speak.

Q Biomed Inc shares eased 1.27% to US$4.65 on the day.

View full QBIO profile View Profile

Q BioMed Inc Timeline

Related Articles

Harley Street sign
December 07 2017
The injection will bankroll the continuing technical development of the firm’s first LIGHT system and its installation at the Harley Street Proton Therapy Centre
1-Operation.jpg
January 18 2017
Deltex’s overseas sales are booming but its previously dominant NHS revenues are dropping off
couple looking at pregnancy test
November 13 2017
The proceeds from the fundraiser will be used to expand in the People's Republic and will invested in product development

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use